These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 19463377

  • 1. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
    Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C.
    JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
    [Abstract] [Full Text] [Related]

  • 2. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O.
    JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
    [Abstract] [Full Text] [Related]

  • 3. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
    Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B.
    J Thromb Haemost; 2010 Feb; 8(2):351-9. PubMed ID: 19943879
    [Abstract] [Full Text] [Related]

  • 4. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
    Kim IS, Jeong YH, Tantry US, Park Y, Lee DH, Bliden KP, Koh JS, Park JR, Jang JS, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S, Gurbel PA.
    Am Heart J; 2013 Jul; 166(1):95-103. PubMed ID: 23816027
    [Abstract] [Full Text] [Related]

  • 5. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
    Danese E, Fava C, Beltrame F, Tavella D, Calabria S, Benati M, Gelati M, Gottardo R, Tagliaro F, Guidi GC, Cattaneo M, Minuz P.
    J Thromb Haemost; 2016 Feb; 14(2):282-93. PubMed ID: 26576037
    [Abstract] [Full Text] [Related]

  • 6. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
    Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D.
    J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
    [Abstract] [Full Text] [Related]

  • 7. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A, Tello-Montoliu A, Rollini F, Ueno M, Ferreiro JL, Patel R, Desai B, Guzman LA, Bass TA, Angiolillo DJ.
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [Abstract] [Full Text] [Related]

  • 9. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C, Ayral Y, Morguet A, Schultheiss HP, Rauch U.
    Cardiovasc Revasc Med; 2012 Feb; 13(3):159-66. PubMed ID: 22503564
    [Abstract] [Full Text] [Related]

  • 10. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.
    Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F.
    J Am Coll Cardiol; 2008 Apr 08; 51(14):1404-11. PubMed ID: 18387444
    [Abstract] [Full Text] [Related]

  • 11. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, Moro PJ, Lambert M, Alessi MC, Bonnet JL.
    JACC Cardiovasc Interv; 2008 Dec 08; 1(6):649-53. PubMed ID: 19463379
    [Abstract] [Full Text] [Related]

  • 12. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H, Lask S, Engelhardt A, Mügge A.
    Thromb Haemost; 2008 Feb 08; 99(2):357-62. PubMed ID: 18278186
    [Abstract] [Full Text] [Related]

  • 13. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B.
    J Thromb Haemost; 2012 Apr 08; 10(4):529-42. PubMed ID: 22260716
    [Abstract] [Full Text] [Related]

  • 14. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D, Capranzano P, Kodali M, Dharmashankar K, Charlton RK, Bass TA, Angiolillo DJ.
    JACC Cardiovasc Interv; 2012 Mar 08; 5(3):293-300. PubMed ID: 22440495
    [Abstract] [Full Text] [Related]

  • 15. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G.
    JACC Cardiovasc Interv; 2013 Feb 08; 6(2):158-65. PubMed ID: 23428007
    [Abstract] [Full Text] [Related]

  • 16. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G, Rostoff P, Undas A, Piwowarska W.
    J Am Coll Cardiol; 2010 Apr 20; 55(16):1671-8. PubMed ID: 20394870
    [Abstract] [Full Text] [Related]

  • 17. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
    El Ghannudi S, Ohlmann P, Jesel L, Radulescu B, El Adraa E, Crimizade U, Wiesel ML, Gachet C, Morel O.
    Atherosclerosis; 2011 Aug 20; 217(2):465-72. PubMed ID: 21524751
    [Abstract] [Full Text] [Related]

  • 18. Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study.
    Hu C, Zhang X, Liu Y, Gao Y, Zhao X, Zhou H, Luo Y, Liu Y, Wang X.
    BMC Cardiovasc Disord; 2018 Jun 18; 18(1):120. PubMed ID: 29914380
    [Abstract] [Full Text] [Related]

  • 19. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, Bonnet JL, Alessi MC.
    JACC Cardiovasc Interv; 2013 Aug 18; 6(8):854-63. PubMed ID: 23968703
    [Abstract] [Full Text] [Related]

  • 20. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
    Ueno M, Ferreiro JL, Tomasello SD, Tello-Montoliu A, Capodanno D, Seecheran N, Kodali M, Dharmashankar K, Desai B, Charlton RK, Bass TA, Angiolillo DJ.
    JACC Cardiovasc Interv; 2011 Aug 18; 4(8):905-12. PubMed ID: 21851906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.